Search results for: Multi-Indication Medicines
Filter search results
Evidence on Valued Based Pricing and Reimbursement Schemes
30 September 2011
…A. (2011) Literature review on Patient Access Schemes, Flexible Pricing Schemes and risk sharing agreements for medicines. Poster presented PPRI Conference 2011. Vienna. 29-30 September. Related OHE research: Operationalising Value…
Join OHE for Its 50th Anniversary Annual Lecture with Sir Michael Rawlins
12 April 2012
…the “gold standard”, instead urging a more pragmatic approach. Sir Michael’s experience – as a clinician, chair of the Committee on Safety of Medicines, and chair of NICE — uniquely…
Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?
1 May 2012
…practice and expected production cost, rather than assessments of value. The paper discusses how a value based pricing (VBP) framework for efficient use and pricing of medicines also might be…
HTAinSite: Recent Changes in the Database of NICE Decisions
7 June 2012
…about HTAinSite, in May 2010, the service has evolved in important ways. Added, for example, is the option of including the decisions of the Scottish Medicines Consortium (SMC) in the…
Spotlight on OHE: Development and Use of Measures of Health Worldwide
16 July 2012
…that when implemented in the UK in 2014, VBP will broaden the definition of value of medicines beyond health effects. The use of evidence in decision making was the subject…
OHE has an Opening for an Economist
4 September 2012
…sector; familiarity with HTA and medicines pricing and reimbursement in practice in one or more countries; strong quantitative skills Applications must be received by Monday, 24 September 2012. Interviews for…
New Research by OHE and University of Glasgow on cost of QALYs in Scotland
17 December 2012
…importance, especially given the Government’s desire to move towards “value based” pricing of new medicines in the future. The threshold may be thought of as the incremental cost per QALY…
Review of Plans for Refining Patient-Reported Outcomes Measures
19 February 2013
…medicines. The EQ-5D is the principal instrument for measuring health related quality of life for HTA purposes, making planned developments in EQ-5D instruments and value sets important in decision making….
OHE Welcomes Professors Rawlins and Smith to its Policy Board
6 May 2013
…2013. A physician and pharmacologist, Sir Michael has provided insight in numerous roles, including as head of both the Committee on Safety of Medicines and the Advisory Council on the…